Cannabis producer Khiron Life Sciences Corp. today announced it has obtained authorization from the Colombian government to be the first in the country to commercialize psychoactive cannabis for both domestic and export purposes. Prior to this approval, commercial producers of cannabis were all confined to selling only product that tested with less than a negligible 1% THC, the psychoactive property in marijuana.
The pioneering event will allow Khiron to provide cannabis extract with high THC to treat up to 15,000 initial patients domestically through the Latin American Institute of Neurology and the Nervous System (ILANS). Considered one of the most respected and largest health service provider networks in Colombia and Latin America, the clinics will use THC-abundant cannabis – ranging from 5 to 20% THC – to treat neurologic conditions, including sleep disorders, neuropathic pain, epilepsy, multiple sclerosis and Parkinson’s disease.
– Read the entire article at Forbes.